Terminology Service for NFDI4Health

Cytidine Analog RX-3117

Go to external page http://purl.obolibrary.org/obo/NCIT_C113444


An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, the cytidine analog RX-3117 is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway. [ ]

Term info

Label

Cytidine Analog RX-3117

Synonyms
  • 4-Amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl)pyrimidin-2(1H)-one
  • Cytidine Analog RX-3117
  • Fluorocyclopentenylcytosine
  • RX-3117
  • TV-1360
Subsets

NCIT_C116978, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712

CAS Registry

865838-26-2

Display Name

Cytidine Analog RX-3117

Preferred Name

Cytidine Analog RX-3117

Semantic Type

Pharmacologic Substance, Nucleic Acid, Nucleoside, or Nucleotide

UMLS CUI

C3834251

code

C113444